CASI Pharmaceuticals Transitioning to OTC Markets: Pursuing Growth and Investor Engagement Opportunities

### CASI Pharmaceuticals Adjusts Course: Embracing New Opportunities on OTC Markets

CASI Pharmaceuticals Inc. is undergoing a strategic transition as it announces its move to the OTC Markets Group following a formal delisting from Nasdaq. This decision, resulting in a 24.48% increase in after-hours trading, closes at $0.25 per share. The shift to OTC trading reflects CASI's proactive approach to ensure continued operations and investor accessibility amid challenges faced in meeting Nasdaq's stringent listing requirements. Regulatory hurdles and market dynamics have pushed the company to adapt swiftly, signaling its intent to maintain shareholder value and broaden engagement with potential investors.

The transition to the OTC Markets positions CASI within a more flexible trading environment, allowing it to potentially attract a new audience of investors while navigating the difficulties accompanied by its previous standing on Nasdaq. The management views this move as essential in securing its financial viability and enabling further growth. While a delisting often raises concerns over a company's stability, CASI's leadership assures stakeholders that this strategic decision is part of a broader plan aimed at revitalizing and reinforcing its market presence in the competitive pharmaceutical landscape.

As CASI Pharmaceuticals embarks on this new chapter, market observers are keenly watching how the company performs on the OTC platform. The company's recent stock spike indicates a level of optimism among investors concerning CASI's capability to capitalize on this transition and effectively manage the challenges ahead. The focus will likely be on how the company communicates its strategic initiatives and operational updates to maintain investor confidence and navigate the evolving dynamics of the pharmaceutical sector.

In addition to its market maneuvering, CASI Pharmaceuticals is actively pursuing avenues to enhance its product pipeline and development strategy. This deliberate focus on growth initiatives could bolster the company’s standing in the crowded pharmaceutical space.

Stakeholders remain hopeful that CASI's shift to OTC trading is a stepping stone towards recovery and renewed focus on value creation for shareholders, underscoring the company's commitment to navigating a complex and shifting market landscape.